Bicara Therapeutics Inc (BCAX) is trading down at $17.61 (-1.68%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
| FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|
| Income statement | |||
| Operating income | −$39.9M | −$82.4M | −$155.6M |
| Net income | −$52.0M | −$68.0M | −$137.9M |
| EPS (diluted) | −$89.61 | −$4.05 | −$2.52 |
| Balance sheet | |||
| Cash and equivalents | $230.4M | $489.7M | $96.7M |
| Total assets | $234.0M | $510.0M | $431.0M |
| Total liabilities | $15.5M | $18.1M | $29.5M |
| Shareholders' equity | −$148.8M | $491.9M | $401.5M |
| Cash flow | |||
| Operating cash flow | −$45.6M | −$74.8M | −$106.8M |
| Capital expenditure | $586.0K | $71.0K | $280.0K |
| Free cash flow | −$46.2M | −$74.8M | −$107.1M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$20.6M | −$26.6M | −$41.8M | −$32.0M | −$40.7M | −$41.1M | −$60.2M | −$60.0M |
| Net income | −$17.5M | −$21.0M | −$36.8M | −$27.4M | −$36.3M | −$37.4M | −$56.2M | −$55.4M |
| EPS (diluted) | −$1.60 | $35.50 | −$0.68 | −$0.50 | −$0.67 | −$0.67 | −$0.93 | −$0.82 |
| Balance sheet | ||||||||
| Cash and equivalents | $520.8M | $489.7M | $462.1M | $436.6M | $171.7M | $96.7M | $323.5M | $96.6M |
| Total assets | $524.2M | $510.0M | $478.1M | $453.6M | $424.7M | $431.0M | $553.6M | $512.2M |
| Total liabilities | $14.6M | $18.1M | $19.1M | $18.4M | $21.9M | $29.5M | $39.6M | $43.5M |
| Shareholders' equity | $509.6M | $491.9M | $459.0M | $435.2M | $402.8M | $401.5M | $514.0M | $468.8M |
| Cash flow | ||||||||
| Operating cash flow | −$17.2M | −$30.0M | −$28.1M | −$25.6M | −$29.2M | −$23.9M | −$37.5M | −$44.2M |
| Capital expenditure | $8.00K | $40.0K | $0 | $0 | $42.0K | $238.0K | $60.0K | $60.0K |
| Free cash flow | −$17.2M | −$30.1M | −$28.1M | −$25.6M | −$29.3M | −$24.1M | −$37.6M | −$44.3M |
From Bicara Therapeutics Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Bicara Therapeutics Inc in our feed yet.